Indian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy’s and Cipla saw significant drops in their net profits and operating margins. However, their domestic businesses continued to perform well, offering a positive outlook. Obesity therapies and specialty product launches are expected to drive future growth for these companies. Analysts have consequently reduced earnings forecasts for the upcoming fiscal years.
Indian stock markets deliver negative returns for two years, worst since 2012, ET analysis reveals
Indian stock markets have disappointed investors with negative returns over two years. The Sensex has shown its worst two-year performance since 2012. Indices have not
August 25, 2026